文献速递淋巴瘤

Pirtobrutinib对比伊布替尼治疗初治及复发难治CLL/SLL

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
PubMed 文献 · J Clin Oncol · 2025-12-07

这项随机头对头研究纳入662例BTKi初治的CLL/SLL患者,1:1接受pirtobrutinib或伊布替尼。主要终点IRC-ORR在ITT人群和R/R人群均达到非劣效,pirtobrutinib组ORR更高,研究者评估PFS趋势 favoring pirtobrutinib,房颤/房扑和高血压发生率更低。

要点

  • pirtobrutinib在BTKi初治CLL/SLL中IRC-ORR非劣效于伊布替尼。
  • 研究者评估PFS趋势 favoring pirtobrutinib,尤其初治人群。
  • pirtobrutinib组房颤/房扑和高血压不良事件率更低。

核心结论

  • pirtobrutinib对比伊布替尼在BTKi初治CLL/SLL中IRC-ORR达到非劣效,早期PFS趋势 favoring pirtobrutinib,安全性良好。

研究设计与样本

  • 随机、1:1头对头比较pirtobrutinib与伊布替尼的临床试验,纳入662例BTKi初治的CLL/SLL患者,包括初治和复发/难治人群。

主要发现

  • TN人群(n=225)IRC-ORR:pirtobrutinib 92.9%(95%CI 86.4-96.9)vs 伊布替尼85.8%(95%CI 78.0-91.7)。
  • 研究者评估PFS的HR:ITT 0.57(95%CI 0.39-0.83),R/R 0.73(95%CI 0.47-1.13),TN 0.24(95%CI 0.10-0.59)。
  • pirtobrutinib组房颤/房扑和高血压不良事件率低于伊布替尼组。

关键数值与推荐

  • 主要终点为IRC评估的ORR,在ITT人群和R/R人群中均达到非劣效。

临床怎么用

  • 对于BTKi初治的CLL/SLL患者,pirtobrutinib提供了与伊布替尼相当的疗效且心脏相关不良事件(房颤/房扑、高血压)更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received prior covalent BTKi. We report results, to our knowledge, from the first randomized head-to-head comparison of pirtobrutinib versus ibrutinib in BTKi-naïve CLL/SLL in both treatment-naïve (TN) patients and patients with relapsed/refractory (R/R) disease. PATIENTS AND METHODS: Patients (N = 662) were randomly assigned 1:1 to receive pirtobrutinib or ibrutinib. All patients were BTKi-naïve. Primary end points were overall response rate (ORR) by independent review committee (IRC) among all randomly assigned patients (intention to treat [ITT]) and in patients with R/R disease. RESULTS: The study met its primary end points, demonstrating statistically significant noninferiority (NI) of IRC-ORR for pirtobrutinib versus ibrutinib in both the ITT (87.0% [95% CI, 82.9 to 90.4] v 78.5% [95% CI, 73.7 to 82.9]; ORR ratio = 1.11 [95% CI, 1.03 to 1.19]; two-sided P < .0001) and R/R populations (n = 437; 84.0% [95% CI, 78.5 to 88.6] v 74.8% [95% CI, 68.5 to 80.4]; ORR ratio = 1.12 [95% CI, 1.02 to 1.24]; two-sided P < .0001). In TN patients (n = 225), IRC-ORR was 92.9% (95% CI, 86.4 to 96.9) with pirtobrutinib versus 85.8% (95% CI, 78.0 to 91.7) with ibrutinib. Investigator assessed ORR results were consistent. Investigator-assessed progression-free survival (PFS) favored pirtobrutinib in the ITT (hazard ratio [HR], 0.57 [95% CI, 0.39 to 0.83]), R/R (HR, 0.73 [95% CI, 0.47 to 1.13]), and TN (HR, 0.24 [95% CI, 0.10 to 0.59]) populations. Cardiac adverse event rates of atrial fibrillation/flutter and hypertension were lower with pirtobrutinib. CONCLUSION: Pirtobrutinib demonstrated NI of ORR versus ibrutinib, with a favorable early PFS trend, particularly in TN patients, and a favorable safety profile including low rates of atrial fibrillation and hypertension.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Woyach JA, Qiu L, Grosicki S, et al. Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol. 2025. PMID: 41353787. doi:10.1200/JCO-25-02477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。